JP2011505846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505846A5 JP2011505846A5 JP2010538304A JP2010538304A JP2011505846A5 JP 2011505846 A5 JP2011505846 A5 JP 2011505846A5 JP 2010538304 A JP2010538304 A JP 2010538304A JP 2010538304 A JP2010538304 A JP 2010538304A JP 2011505846 A5 JP2011505846 A5 JP 2011505846A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- molecule
- disease
- growth factor
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000001413 amino acids Chemical group 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102000001301 EGF receptor Human genes 0.000 claims 6
- 108060006698 EGF receptor Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000004055 small Interfering RNA Substances 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims 5
- 108020004459 Small interfering RNA Proteins 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000005340 mucopolysaccharidosis III Diseases 0.000 claims 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 3
- -1 Bcl-xL Proteins 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108091008606 PDGF receptors Proteins 0.000 claims 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 102000016562 Sorting nexin-6 Human genes 0.000 claims 2
- 108050006109 Sorting nexin-6 Proteins 0.000 claims 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims 2
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims 2
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- PAEZRCINULFAGO-OAQYLSRUSA-N (R)-homocamptothecin Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC=CC=C3N=C21 PAEZRCINULFAGO-OAQYLSRUSA-N 0.000 claims 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 1
- 229960005532 CC-1065 Drugs 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 claims 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 102000010410 Nogo Proteins Human genes 0.000 claims 1
- 108010077641 Nogo Proteins Proteins 0.000 claims 1
- 102000000343 Nogo Receptor 1 Human genes 0.000 claims 1
- 108010041199 Nogo Receptor 1 Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000001828 Sly syndrome Diseases 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 1
- 229940122429 Tubulin inhibitor Drugs 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 102000013814 Wnt Human genes 0.000 claims 1
- 108050003627 Wnt Proteins 0.000 claims 1
- 208000026589 Wolman disease Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- OPQNCARIZFLNLF-UHFFFAOYSA-N ansamitocin P-3 Natural products CN1C(=O)CC(OC(=O)C(C)C)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 OPQNCARIZFLNLF-UHFFFAOYSA-N 0.000 claims 1
- OPQNCARIZFLNLF-JBHFWYGFSA-N ansamitocin P3 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)C(C)C)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 OPQNCARIZFLNLF-JBHFWYGFSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 101150024228 mdm2 gene Proteins 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 claims 1
- 208000027333 mucopolysaccharidosis type IIID Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960001237 podophyllotoxin Drugs 0.000 claims 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 1
- 239000012217 radiopharmaceutical Substances 0.000 claims 1
- 229940121896 radiopharmaceutical Drugs 0.000 claims 1
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 1
- 102000009929 raf Kinases Human genes 0.000 claims 1
- 108010077182 raf Kinases Proteins 0.000 claims 1
- 102000016914 ras Proteins Human genes 0.000 claims 1
- 108010014186 ras Proteins Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 102000009076 src-Family Kinases Human genes 0.000 claims 1
- 108010087686 src-Family Kinases Proteins 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US882507P | 2007-12-20 | 2007-12-20 | |
| PCT/CA2008/002269 WO2009079790A1 (en) | 2007-12-20 | 2008-12-19 | Polypeptide-nucleic acid conjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505846A JP2011505846A (ja) | 2011-03-03 |
| JP2011505846A5 true JP2011505846A5 (enExample) | 2012-02-09 |
Family
ID=40800623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538304A Pending JP2011505846A (ja) | 2007-12-20 | 2008-12-19 | ポリペプチド−核酸コンジュゲートおよびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110039785A1 (enExample) |
| EP (1) | EP2235175A4 (enExample) |
| JP (1) | JP2011505846A (enExample) |
| CN (1) | CN101946001A (enExample) |
| AU (1) | AU2008340943A1 (enExample) |
| BR (1) | BRPI0821310A2 (enExample) |
| CA (1) | CA2709635A1 (enExample) |
| MX (1) | MX2010006925A (enExample) |
| RU (1) | RU2010129761A (enExample) |
| WO (1) | WO2009079790A1 (enExample) |
| ZA (1) | ZA201004609B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007322A (es) | 2003-01-06 | 2006-02-17 | Angiochem Inc | Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro. |
| DK2351844T3 (da) | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler |
| ATE551422T1 (de) | 2005-02-18 | 2012-04-15 | Angiochem Inc | Aprotininpolypeptide zum transport einer verbindung durch die blut-hirn-schranke |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| ES2744225T3 (es) | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| CA2666841A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| RU2011118056A (ru) | 2008-10-15 | 2012-11-27 | Ангиокем Инк. | Конъюгаты агонистов glp-1 и их применение |
| CN102307904A (zh) | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
| CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
| US9173891B2 (en) | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| CN102596993A (zh) * | 2009-07-02 | 2012-07-18 | 安吉奥开米公司 | 多聚体肽结合物以及其应用 |
| AU2010305284A1 (en) * | 2009-10-06 | 2012-05-03 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| MX2012011515A (es) * | 2010-04-09 | 2012-11-06 | Merck Sharp & Dohme | Entidades quimicas simples novedosas y metodos de suministro de oligonucleotidos. |
| EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| WO2011131693A2 (en) | 2010-04-19 | 2011-10-27 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| WO2012000118A1 (en) | 2010-07-02 | 2012-01-05 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CN103619356B (zh) * | 2011-05-05 | 2017-09-12 | 萨勒普塔医疗公司 | 肽寡核苷酸缀合物 |
| US20140259192A1 (en) | 2011-07-12 | 2014-09-11 | Sanofi | Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene |
| ES2632212T3 (es) | 2011-08-04 | 2017-09-11 | Yeda Research And Development Co. Ltd. | miR-135 y composiciones que lo comprenden para el tratamiento de afecciones médicas asociadas con la serotonina |
| JP2015505824A (ja) * | 2011-12-01 | 2015-02-26 | アンジオケム インコーポレーテッド | 標的化リソソーム酵素化合物 |
| HK1200190A1 (en) * | 2011-12-01 | 2015-07-31 | 安吉奥开米公司 | Targeted enzyme compounds and uses thereof |
| JP6195848B2 (ja) * | 2012-01-27 | 2017-09-13 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 糖ポリマーを用いた生体分子の安定化 |
| CN104662151A (zh) * | 2012-06-15 | 2015-05-27 | 安吉奥开米公司 | 靶向的艾杜糖醛酸酶化合物 |
| WO2014026283A1 (en) | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| KR101445265B1 (ko) * | 2012-09-18 | 2014-09-30 | 포항공과대학교 산학협력단 | 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물 |
| MX2015005352A (es) | 2012-10-26 | 2015-10-29 | Nlife Therapeutics S L | Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas. |
| WO2015006641A2 (en) * | 2013-07-12 | 2015-01-15 | Georgia State University Research Foundation, Inc. | Methods and compositions for interference with dna polymerase and dna synthesis |
| CN106715695B (zh) | 2014-02-05 | 2020-07-31 | 耶达研究及发展有限公司 | 用于治疗和诊断的微rna和包含所述微rna的组合物 |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
| CN106282118A (zh) * | 2015-06-24 | 2017-01-04 | 武汉荣实医药科技有限公司 | 阿尔兹海默症关键致病因子app的基因工程细胞株和药物筛选模型 |
| WO2019037133A1 (zh) * | 2017-08-25 | 2019-02-28 | 深圳市博奥康生物科技有限公司 | 靶向沉默APP的shRNA |
| US12458614B2 (en) | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
| EP3480212B1 (en) | 2017-11-03 | 2023-09-27 | Consejo Superior De Investigaciones Científicas | Il13ralpha2 peptide and its uses |
| WO2020008083A1 (es) | 2018-07-05 | 2020-01-09 | Consejo Superior De Investigaciones Científicas | Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas |
| CN111208284B (zh) * | 2018-11-22 | 2021-08-24 | 北京大学 | 糖代谢标记探针、包含其的试剂盒及其应用 |
| KR102320650B1 (ko) * | 2019-10-16 | 2021-11-04 | 주식회사 시선테라퓨틱스 | 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체 및 이를 포함하는 조성물 |
| CA3204415A1 (en) * | 2021-01-18 | 2022-07-21 | Alon Chen | Modified mir-135, conjugated form thereof, and uses of same |
| CA3173359A1 (en) * | 2021-06-07 | 2022-12-15 | Dietrich A. Stephan | Peptide nucleic acid therapeutics for trinucleotide repeat disorders |
| EP4180527B1 (en) * | 2021-11-11 | 2025-07-09 | Hangzhou Chichuang Biotechnology Co., Ltd. | Synthesis method of targeted drug ncovshrna·2ace2 |
| WO2024042466A1 (en) * | 2022-08-22 | 2024-02-29 | University Of Tartu | Brain penetrating peptides and methods of use thereof |
| WO2025090567A1 (en) * | 2023-10-23 | 2025-05-01 | Ophidion Inc. | LOW DOSE siRNA TREATMENTS OF HUNTINGTON'S DISEASE |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030170891A1 (en) * | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| WO2004094595A2 (en) * | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
| EP1638605B1 (en) * | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| MXPA06012605A (es) * | 2004-05-04 | 2006-12-15 | Nastech Pharm Co | Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas. |
| ATE551422T1 (de) * | 2005-02-18 | 2012-04-15 | Angiochem Inc | Aprotininpolypeptide zum transport einer verbindung durch die blut-hirn-schranke |
| ES2744225T3 (es) * | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| CA2621694A1 (en) * | 2005-09-08 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
| CA2688344C (en) * | 2007-05-29 | 2019-09-03 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
-
2008
- 2008-12-19 CA CA2709635A patent/CA2709635A1/en not_active Abandoned
- 2008-12-19 BR BRPI0821310-0A patent/BRPI0821310A2/pt not_active IP Right Cessation
- 2008-12-19 WO PCT/CA2008/002269 patent/WO2009079790A1/en not_active Ceased
- 2008-12-19 EP EP08865493A patent/EP2235175A4/en not_active Withdrawn
- 2008-12-19 MX MX2010006925A patent/MX2010006925A/es not_active Application Discontinuation
- 2008-12-19 CN CN2008801270674A patent/CN101946001A/zh active Pending
- 2008-12-19 US US12/808,439 patent/US20110039785A1/en not_active Abandoned
- 2008-12-19 AU AU2008340943A patent/AU2008340943A1/en not_active Abandoned
- 2008-12-19 JP JP2010538304A patent/JP2011505846A/ja active Pending
- 2008-12-19 RU RU2010129761/10A patent/RU2010129761A/ru not_active Application Discontinuation
-
2010
- 2010-06-30 ZA ZA2010/04609A patent/ZA201004609B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505846A5 (enExample) | ||
| RU2010129761A (ru) | Конъюгаты полипептидов с нуклеиновыми кислотами и их применение | |
| Ma et al. | An intelligent DNA nanorobot with in vitro enhanced protein lysosomal degradation of HER2 | |
| Li et al. | Enhanced in vivo blood–brain barrier penetration by circular Tau–transferrin receptor bifunctional aptamer for tauopathy therapy | |
| Park et al. | Gemcitabine-incorporated G-quadruplex aptamer for targeted drug delivery into pancreas cancer | |
| Saunders et al. | Barriers in the brain: a renaissance? | |
| Baker Jr | Dendrimer-based nanoparticles for cancer therapy | |
| JP2008529539A5 (enExample) | ||
| Zhuo et al. | Recent advances in SELEX technology and aptamer applications in biomedicine | |
| Patil et al. | Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery | |
| JP2013506697A5 (enExample) | ||
| Wu et al. | Potential diagnostic and therapeutic applications of oligonucleotide aptamers in breast cancer | |
| JP2012521217A5 (enExample) | ||
| RU2016144055A (ru) | Конъюгаты лекарственного средства с наночастицами | |
| RU2015100231A (ru) | Способ отбора и получения селективных и мультиспецифических терапевтических молекул с заданными свойствами, включающих по меньшей мере две различные нацеливающие группировки, и их применения | |
| Hays et al. | Aptamers and glioblastoma: Their potential use for imaging and therapeutic applications | |
| MX374776B (es) | Un método in vitro para criba de un anticuerpo anti-axl, o un fragmento de enlace del mismo, capaz de suministrar o internalizar una molécula de interés en una célula de mamífero. | |
| WO2013012961A3 (en) | Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | |
| Yang et al. | Engineering polymeric aptamers for selective cytotoxicity | |
| CN110354268B (zh) | 一种核酸适配体及其环形二价核酸适配体-药物的偶联系统与应用 | |
| CN105188764B (zh) | Dna嵌入剂的细胞递送 | |
| JP2015513919A (ja) | 膵癌細胞への治療的送達および診断的送達のためのｒｎａアプタマー | |
| Cruz-Hernandez et al. | Aptamers as theragnostic tools in prostate cancer | |
| Tang et al. | Nanoparticle-based RNAi therapeutics targeting cancer stem cells: Update and prospective | |
| JP2018525381A5 (enExample) |